SummitTX Capital L.P. Acquires 193,313 Shares of Celldex Therapeutics, Inc. $CLDX

SummitTX Capital L.P. grew its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 446.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 236,637 shares of the biopharmaceutical company’s stock after purchasing an additional 193,313 shares during the period. SummitTX Capital L.P.’s holdings in Celldex Therapeutics were worth $7,506,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Celldex Therapeutics by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after buying an additional 680 shares during the period. Millennium Management LLC boosted its position in Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock valued at $7,259,000 after buying an additional 306,330 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock valued at $2,383,000 after buying an additional 14,979 shares during the period. Russell Investments Group Ltd. grew its stake in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new position in Celldex Therapeutics in the 2nd quarter worth about $347,000.

Celldex Therapeutics Price Performance

Celldex Therapeutics stock opened at $35.28 on Monday. The business has a fifty day moving average of $33.64 and a two-hundred day moving average of $30.71. The firm has a market cap of $2.77 billion, a P/E ratio of -8.28 and a beta of 0.90. Celldex Therapeutics, Inc. has a twelve month low of $19.72 and a twelve month high of $40.30.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.80 million. Equities analysts expect that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CLDX. Canaccord Genuity Group decreased their price target on shares of Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Guggenheim increased their price objective on Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Cantor Fitzgerald reduced their price objective on Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a report on Wednesday, July 22nd. Morgan Stanley decreased their target price on Celldex Therapeutics from $44.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday, July 22nd. Finally, Wells Fargo & Company lowered their target price on Celldex Therapeutics from $54.00 to $48.00 and set an “overweight” rating for the company in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $52.77.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.